organization · Reporting owner
InCube Labs, L.L.C.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | 10% owner | February 03, 2022 | February 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date February 03, 2022 · Filed February 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 13,923 |
Reported balance
After 2022-02-03 transaction · row 1
1 source rowRow 1 · 2022-02-03 · Other · Acquired 13,923 · Balance 13,923 F1: Received in kind pro rata distribution from Biologix Partners, LP (3,181 shares of Class A Common Stock) and VH Rani, LP. (10,742 shares of Class A Common Stock), to its limited partners. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in kind pro rata distribution from Biologix Partners, LP (3,181 shares of Class A Common Stock) and VH Rani, LP. (10,742 shares of Class A Common Stock), to its limited partners.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2022 Filed Feb 8, 2022 02:36 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 13,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007636 · doc4.xml · nonDerivative · entry 1 InCube Labs, L.L.C. · CIK 0001873082 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,923 F1 · kind: Received in kind pro rata distribution from Biologix Partners, LP (3,181 shares of Class A Common Stock) and VH Rani, LP. (10,742 shares of Class A Common Stock), to its limited partners. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.